C21 InvestmentsCXXIF +10.72%31 Interest Coverage is 5.08 as of Mar. 2026, which is 37% below its 10-year median of 8.06. GuruFocus rates CXXIF with a GF Score™ of 31/100 and a GF Value™ of $0.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 686 Drug Manufacturers companies, C21 Investments ranks worse than 74.34% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. C21 Investments's
Operating Income
for the
three
months ended in Mar. 2026 was $0.49 Mil. C21 Investments's Interest Expense for the
three
months ended in Mar. 2026 was $-0.10 Mil.
C21 Investments's interest coverage for the quarter that ended in Mar. 2026 was 5.08.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for C21 Investments's Interest Coverage or its related term are showing as below:
CXXIF'
s Interest Coverage Range Over the Past 10 Years
Min: 1.59 Med: 8.06 Max: No Debt
Current: 4.08
CXXIF's Interest Coverage is ranked worse than 74.34% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs CXXIF: 4.08
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
C21 Investments Interest Coverage Related Terms
C21 Investments Interest Coverage Historical Data
* Premium members only.
The historical data trend for C21 Investments's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's Interest Coverage distribution charts can be found below:
* The bar in red indicates where C21 Investments's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a Interest Coverage of 5.08 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on C21 Investments and its competitors. This is 37% below median its historical median of 8.06. Over the past decade, C21 Investments' Interest Coverage has ranged from 1.59 to 10,000.00. According to the industry distribution chart, C21 Investments ranks #510 out of 686 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is C21 Investments' Interest Coverage too high?
C21 Investments' current Interest Coverage of 5.08 is 37% below median its 10-year median of 8.06. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 10,000.00. The Drug Manufacturers industry median Interest Coverage is 12.73. C21 Investments' value of 5.08 is 60.1% below this industry median. Based on the distribution chart, C21 Investments ranks #510 out of 686 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #510 out of 686 companies for Interest Coverage. This places C21 Investments in the lower half of its industry. The industry median Interest Coverage is 12.73. C21 Investments' value of 5.08 is 60.1% below this benchmark. Historically, C21 Investments' own Interest Coverage has ranged from 1.59 to 10,000.00 over the past decade. While the company's 10-year median is 8.06 vs. the industry median of 12.73, C21 Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current Interest Coverage of 5.08 is 60.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current Interest Coverage is 5.08, which is 37% below median its own 10-year median of 8.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.24 — trading 13% below its estimated fair value. The current Interest Coverage is 5.08, which is 37% below median its 10-year median of 8.06 and 60.1% below the Drug Manufacturers industry median of 12.73. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For C21 Investments (CXXIF), the current Interest Coverage is 5.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.24 is trading 13% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
Interest Coverage: 5.08 (37% below median its 10-year median of 8.06)
GF Value™: $0.28 vs. price of $0.24 (13% below fair value)
Industry Position: 60.1% below the Drug Manufacturers median (#510 of 686)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
